Monitoring of PrEP by nurses
OtherMonitoring of PrEP by nurses
NCT Number: NCT07695493
Assess the quality of care and the satisfaction of patients and caregivers when the monitoring of people on HIV pre-exposure prophylaxis (PrEP) is provided by nurses instead of physicians
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
The HIV/AIDS epidemic remains uncontrolled in France, with approximately 5,000 to 6,000 new cases reported each year. Since January 2016, HIV pre-exposure prophylaxis (PrEP)-which involves taking a single oral tablet containing two antiretroviral drugs-has been available in France. The effectiveness of this PrEP has been demonstrated, with a relative reduction in HIV incidence of nearly 97% when PrEP is taken correctly.
However, only nearly 50,000 people are using PrEP in France in 2024, which is far short of the targets needed to control the epidemic. Indeed, the population of men who have sex with men (MSM) at risk of HIV infection is estimated at over 200,000, and the number of heterosexuals on PrEP is negligible, even though 40% of new HIV diagnoses involve heterosexuals from countries with high prevalence (Sub-Saharan Africa).
Furthermore, these 50,000 people on PrEP represent only 64% of the >120,000 people who have started PrEP since 2016, indicating that many have discontinued this prophylaxis over time. One of the challenges in implementing PrEP stems from the small number of trained hospital and primary care physicians and their limited time availability to provide a PrEP care.
Since 2022, PrEP training programs in medical settings, involving nurses, have been implemented to train them to monitore people on PrEP. This involvement of nurses would help increase the availability of PrEP, free up doctors' time for complex cases, and enhance the value of nursing work.
However, there has been no evaluation of this care provided by nurses to people on PrEP in terms of quality, acceptability, satisfaction among people on PrEP, nurses, and doctors, or its cost-effectiveness.
The aim of our study is therefore to assess whether the care provided to subjects on PrEP by these nurses is as good, well-accepted, and satisfactory for subjects and caregivers as it would be if the care were provided solely by physicians.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Monitoring of PrEP by nurses
Monitoring of PrEP by physicians
Time frame: Up to 12 months
Compliance to PrEP is defined by a composite criterion comprising:
Time frame: At baseline
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
Time frame: At 6 months
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
Time frame: At 12 months
Assessed by PCR testing for Chlamydia and Neisseria gonorrhoeae, and serological testing for syphilis)
Time frame: At baseline
Plasma creatine level
Time frame: At 6 months
Plasma creatine level
Time frame: At 12 months
Plasma creatine level
Time frame: At 12 months
Number of patient visits completed during the year and Tenofovir diphosphate concentrations
Time frame: Up to 12 months
Number of participants who discontinued follow-up and reasons for discontinuation
Time frame: Up to 12 months
HIV infection during follow up (positive serology or HIV RNA)
Time frame: Up to 12 months
From the perspectives of the healthcare system, patients, and health insurance : Incremental or decremental cost-effectiveness ratio (Cost per patient, Time spent in consultations, Number of prescribed labs and tests, and Number and duration of any hospitalizations…)
Time frame: At 12 months
Focus groups
Contact information is provided by the study sponsor or research team.
Bénédicte Loze, Nurse
CONTACT
01.42.49.48.52 ext. +33
Jérôme Lambert, MD PhD
CONTACT
0142499742 ext. +33
Assistance Publique - Hôpitaux de Paris
Other
Acronym: PREVI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07209267
Blood-Borne Infections, Communicable Diseases
Atlanta, Georgia, United States
View Trial DetailsNCT07620652
Blood-Borne Infections, Communicable Diseases
Modena, MO, Italy
View Trial DetailsNCT07681908
Behavior, Blood-Borne Infections
San Clemente, California, United States
View Trial DetailsNCT07658976
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Los Angeles, California, United States
View Trial Details